WO2006008294A3 - Utilisation diagnostique et therapeutique du slim pour des maladies neurodegeneratives - Google Patents

Utilisation diagnostique et therapeutique du slim pour des maladies neurodegeneratives Download PDF

Info

Publication number
WO2006008294A3
WO2006008294A3 PCT/EP2005/053468 EP2005053468W WO2006008294A3 WO 2006008294 A3 WO2006008294 A3 WO 2006008294A3 EP 2005053468 W EP2005053468 W EP 2005053468W WO 2006008294 A3 WO2006008294 A3 WO 2006008294A3
Authority
WO
WIPO (PCT)
Prior art keywords
slim3
disease
alzheimer
provides
neurodegenerative diseases
Prior art date
Application number
PCT/EP2005/053468
Other languages
English (en)
Other versions
WO2006008294A2 (fr
Inventor
Der Kammer Heinz Von
Johannes Pohlner
Original Assignee
Evotec Neurosciences Gmbh
Der Kammer Heinz Von
Johannes Pohlner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh, Der Kammer Heinz Von, Johannes Pohlner filed Critical Evotec Neurosciences Gmbh
Priority to EP05777722A priority Critical patent/EP1771578A2/fr
Publication of WO2006008294A2 publication Critical patent/WO2006008294A2/fr
Publication of WO2006008294A3 publication Critical patent/WO2006008294A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

La présente invention concerne, d'une part une protéine codée par le gène SLIM3, et d'autre part l'expression différentielle du gène SLIM3 codant pour des protéines SLIM3 dans des régions encéphaliques spécifiques de patients atteints d'Alzheimer. Sur cette base, l'invention concerne un procédé de diagnostic ou de pronostic de la maladie d'Alzheimer chez un sujet, ou d'évaluation de risque accru que le sujet développe la maladie d'Alzheimer. L'invention concerne en outre des traitements thérapeutiques et prophylactiques de la maladie d'Alzheimer et de troubles neurodégénératifs s'y rapportant au moyen du gène SLIM3 et des produits géniques correspondants. L'invention concerne enfin un procédé de recherche systématique de modulateurs de maladie neurodégénératives.
PCT/EP2005/053468 2004-07-23 2005-07-19 Utilisation diagnostique et therapeutique du slim pour des maladies neurodegeneratives WO2006008294A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05777722A EP1771578A2 (fr) 2004-07-23 2005-07-19 Utilisation diagnostique et therapeutique du slim3 pour des maladies neurodegeneratives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59037204P 2004-07-23 2004-07-23
US60/590,372 2004-07-23

Publications (2)

Publication Number Publication Date
WO2006008294A2 WO2006008294A2 (fr) 2006-01-26
WO2006008294A3 true WO2006008294A3 (fr) 2006-10-19

Family

ID=35785591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/053468 WO2006008294A2 (fr) 2004-07-23 2005-07-19 Utilisation diagnostique et therapeutique du slim pour des maladies neurodegeneratives

Country Status (2)

Country Link
EP (1) EP1771578A2 (fr)
WO (1) WO2006008294A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016636A2 (fr) * 2000-08-24 2002-02-28 Evotec Neurosciences Gmbh Application diagnostique et therapeutique d'une proteine membranaire integrale associee aux caveolae a la maladie d'alzheimer et aux troubles neurodegeneratifs associes
WO2003054152A2 (fr) * 2001-12-10 2003-07-03 Nuvelo, Inc. Nouveaux acides nucleiques et polypeptides
WO2003087768A2 (fr) * 2002-04-12 2003-10-23 Mitokor Cibles pour une intervention therapeutique identifiee dans le proteome mitochondrial
WO2003100092A2 (fr) * 2002-05-28 2003-12-04 Evotec Neurosciences Gmbh Utilisation diagnostique et therapeutique de cyp11a1 pour des maladies de neurodegenerescence
EP1491895A1 (fr) * 2003-06-24 2004-12-29 Universitätsklinikum Freiburg Modulation de l'activité des ostéoblastes par Fhl2

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016636A2 (fr) * 2000-08-24 2002-02-28 Evotec Neurosciences Gmbh Application diagnostique et therapeutique d'une proteine membranaire integrale associee aux caveolae a la maladie d'alzheimer et aux troubles neurodegeneratifs associes
WO2003054152A2 (fr) * 2001-12-10 2003-07-03 Nuvelo, Inc. Nouveaux acides nucleiques et polypeptides
WO2003087768A2 (fr) * 2002-04-12 2003-10-23 Mitokor Cibles pour une intervention therapeutique identifiee dans le proteome mitochondrial
WO2003100092A2 (fr) * 2002-05-28 2003-12-04 Evotec Neurosciences Gmbh Utilisation diagnostique et therapeutique de cyp11a1 pour des maladies de neurodegenerescence
EP1491895A1 (fr) * 2003-06-24 2004-12-29 Universitätsklinikum Freiburg Modulation de l'activité des ostéoblastes par Fhl2

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.", NEUROBIOLOGY OF AGING. UNITED STATES 1998 MAR-APR, vol. 19, no. 2, March 1998 (1998-03-01), pages 109 - 116, XP002233088, ISSN: 0197-4580 *
ALBRECHT C ET AL: "Spatio - temporal gene expression profiling in Alzheimer's disease.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, pages Abstract No. 202.18 URL - http://sf, XP008062372 *
CHAN K K ET AL: "Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER, AMSTERDAM, NL, vol. 210, no. 2, 14 April 1998 (1998-04-14), pages 345 - 350, XP004118187, ISSN: 0378-1119 *
DATABASE UniProt [online] 1 November 1997 (1997-11-01), "Four and a half LIM domains protein 2 (FHL-2) (Skeletal muscle LIM- protein 3) (SLIM 3) (LIM-domain protein DRAL).", XP002377336, retrieved from EBI accession no. UNIPROT:FHL2_HUMAN Database accession no. FHL2_HUMAN *
LORING J F ET AL: "A gene expression profile of Alzheimer's disease.", DNA AND CELL BIOLOGY. UNITED STATES NOV 2001, vol. 20, no. 11, November 2001 (2001-11-01), pages 683 - 695, XP002233087, ISSN: 1044-5498 *
TANAHASHI H ET AL: "Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein.", HUMAN MOLECULAR GENETICS. 22 SEP 2000, vol. 9, no. 15, 22 September 2000 (2000-09-22), pages 2281 - 2289, XP002374761, ISSN: 0964-6906 *

Also Published As

Publication number Publication date
WO2006008294A2 (fr) 2006-01-26
EP1771578A2 (fr) 2007-04-11

Similar Documents

Publication Publication Date Title
WO2005108999A3 (fr) Utilisation diagnostique et therapeutique de kcnj6 pour les maladies neurodegeneratives
WO2006125830A3 (fr) Kcnn3 servant de cible diagnostique et therapeutique pour des maladies neurodegeneratives
WO2004070388A8 (fr) Utilisation diagnostique et therapeutique de la proteine scn2b pour des maladies neurodegeneratives
WO2003040183A3 (fr) Composes pour le diagnostic/prevention/traitement de la maladie d'alzheimer
WO2004003563A3 (fr) Utilisation diagnostique et therapeutique de la proteine et du gene ensadin-0581 dans le cadre des maladies neurodegeneratives
WO2004001422A3 (fr) Utilisation, en matiere de diagnostic et de therapie de maladies neurodegeneratives, de la proteine 2 (g3bp2) se fixant au domaine sh3 de la proteine activant la ras gtpase
WO2002016636A3 (fr) Application diagnostique et therapeutique d'une proteine membranaire integrale associee aux caveolae a la maladie d'alzheimer et aux troubles neurodegeneratifs associes
WO2004038411A3 (fr) Utilisations diagnostique et therapeutique d'un gene de l'ensadin-0289 et d'une proteine pour des maladies neurodegeneratives
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2006134128A3 (fr) Methodes faisant appel a des proteines adarb2 cibles pour diagnostiquer et pour pronostiquer des maladies neurodegeneratives
WO2005085472A3 (fr) Utilisation diagnostique et therapeutique du gene et de la proteine mal2 pour les maladies neurodegenerescentes
WO2005030947A3 (fr) Utilisation diagnostique et therapeutique d'une sulfotransferase pour des maladies neurodegeneratives
WO2003087403A3 (fr) Diagnostic et utilisation therapeutique d'une proteine golgi pour des maladies neurodegeneratives
WO2005101014A3 (fr) Diagnostic et utilisation therapeutique de kcnc1 de maladies neurodegeneratives
WO2005059562A3 (fr) Diagnostic et utilisation therapeutique du gene humain hif3alpha et proteines associees contre les maladies neurodegeneratives
ATE464567T1 (de) Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen
WO2006008294A3 (fr) Utilisation diagnostique et therapeutique du slim pour des maladies neurodegeneratives
WO2003100092A3 (fr) Utilisation diagnostique et therapeutique de cyp11a1 pour des maladies de neurodegenerescence
WO2004035823A3 (fr) Utilisation diagnostique et therapeutique des gene et proteine ensadin-0625 destinee a des maladies neurodegeneratives
ATE534751T1 (de) Verwendung von prkx zur diagnose und therapie von alzheimer krankheit
WO2003085131A3 (fr) Utilisation a des fins diagnostiques et therapeutiques de proteines et polynucleotides voutes pour des maladies neurodegeneratives
WO2005071418A3 (fr) Utilisation diagnostique et therapeutique du gene humain dax-1 et proteine pour maladies neurodegeneratives
WO2004020665A3 (fr) Utilisation de polynucleotides et de polypeptides du gene foap-13 pour le diagnostic et la therapie de maladies neurodegeneratives
WO2003069347A3 (fr) Utilisation diagnostique et therapeutique d'une proteine activatrice de secretion vesiculaire dans les maladies neurodegeneratives
WO2003104811A3 (fr) Utilisation diagnostique et therapeutique de la proteine regulatrice de reponse steroidogene aigue pour traiter des maladies neurodegeneratives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005777722

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005777722

Country of ref document: EP